This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by O’Brien, P.
Right arrow Articles by Oyebode, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by O’Brien, P.
Right arrow Articles by Oyebode, F.
Advances in Psychiatric Treatment (2003) 9: 414-423
© 2003 The Royal College of Psychiatrists

Psychotropic medication and the heart

Patrick O’Brien and Femi Oyebode

Patrick O’Brien has recently retired from a post as consultant psychiatrist at Birmingham’s Queen Elizabeth Psychiatric Hospital to enter freelance practice. He is currently consultant psychiatrist for the Forensic Mental Health Service, Leicestershire Partnership NHS Trust (Towers Hospital, Gipsy Lane, Leicester LE5 0TD, UK). Formerly a general practitioner principal, he has a long-standing interest in medical psychiatric practice. He is a member of Lilly Regional Advisory Board and has delivered lectures sponsored by Eli-Lilly Pharmaceuticals. Femi Oyebode is Professor of Psychiatry and Head of the Department of Psychiatry at the University of Birmingham, UK.

Psychotropic literature in recent years has become very concerned with the cardiac safety of certain psychotropic medication. This paper reviews some of the cardiac factors to be considered in the safer selection of psychotropic drugs for the vulnerable patient in everyday clinical practice.




This article has been cited by other articles:


Home page
 Adv. Psychiatr. Treat.Home page
J. Seymour and T. B. Benning
Depression, cardiac mortality and all-cause mortality
Adv. Psychiatr. Treat., March 1, 2009; 15(2): 107 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
L. Solomons, A. Treloar, and R. Noronha
Competence of psychiatric clinicians in interpreting electrocardiograms and QT intervals: can they do this? Does it matter?
Psychiatr. Bull., August 1, 2008; 32(8): 291 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
N. Abdelmawla and A. J. Mitchell
Sudden cardiac death and antipsychotics. Part 2: Monitoring and prevention
Adv. Psychiatr. Treat., March 1, 2006; 12(2): 100 - 109.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
N. Abdelmawla and A. J. Mitchell
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
Adv. Psychiatr. Treat., January 1, 2006; 12(1): 35 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
B. Chadwick, D. G. Waller, and J. G. Edwards
Potentially hazardous drug interactions with psychotropics
Adv. Psychiatr. Treat., November 1, 2005; 11(6): 440 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
M. Connolly and C. Kelly
Lifestyle and physical health in schizophrenia
Adv. Psychiatr. Treat., March 1, 2005; 11(2): 125 - 132.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
P. Madhani, J. Hughes, and C. G. Ballard
Cholinesterase inhibitors and the heart in old age
Adv. Psychiatr. Treat., September 1, 2004; 10(5): 399 - 399.
[Full Text] [PDF]